» Articles » PMID: 38528055

Decreased Calcium Permeability Caused by Biallelic TRPV5 Mutation Leads to Autosomal Recessive Renal Calcium-wasting Hypercalciuria

Overview
Journal Eur J Hum Genet
Specialty Genetics
Date 2024 Mar 26
PMID 38528055
Authors
Affiliations
Soon will be listed here.
Abstract

Hypercalciuria is the most common metabolic risk factor in people with kidney stone disease. Its etiology is mostly multifactorial, although monogenetic causes of hypercalciuria have also been described. Despite the increased availability of genetic diagnostic tests, the vast majority of individuals with familial hypercalciuria remain unsolved. In this study, we investigated a consanguineous pedigree with idiopathic hypercalciuria. The proband additionally exhibited severe skeletal deformities and hyperparathyroidism. Whole-exome sequencing of the proband revealed a homozygous ultra-rare variant in TRPV5 (NM_019841.7:c.1792G>A; p.(Val598Met)), which encodes for a renal Ca-selective ion channel. The variant segregates with the three individuals with hypercalciuria. The skeletal phenotype unique to the proband was due to an additional pathogenic somatic mutation in GNAS (NM_000516.7:c.601C>T; p.(Arg201Cys)), which leads to polyostotic fibrous dysplasia. The variant in TRPV5 is located in the TRP helix, a characteristic amphipathic helix that is indispensable for the gating movements of TRP channels. Biochemical characterization of the TRPV5 p.(Val598Met) channel revealed a complete loss of Ca transport capability. This defect is caused by reduced expression of the mutant channel, due to misfolding and preferential targeting to the proteasome for degradation. Based on these findings, we conclude that biallelic loss of TRPV5 function causes a novel form of monogenic autosomal recessive hypercalciuria, which we name renal Ca-wasting hypercalciuria (RCWH). The recessive inheritance pattern explains the rarity of RCWH and underscores the potential prevalence of RCWH in highly consanguineous populations, emphasizing the importance of exploration of this disorder within such communities.

Citing Articles

Looking back at 2024 in the European Journal of Human Genetics.

McNeill A Eur J Hum Genet. 2025; 33(2):141-143.

PMID: 39972162 PMC: 11839922. DOI: 10.1038/s41431-025-01800-5.


November in EJHG: looking at genetic counsellor training in Europe, novel clinical guidelines and ancestral impact on variant interpretation.

McNeill A Eur J Hum Genet. 2024; 32(11):1343-1344.

PMID: 39562698 PMC: 11577017. DOI: 10.1038/s41431-024-01713-9.


A successful conclusion to the long search for TRPV5 pathogenic variants in monogenic hypercalciuria.

Gorvin C Eur J Hum Genet. 2024; 32(11):1345-1346.

PMID: 38839989 PMC: 11576729. DOI: 10.1038/s41431-024-01613-y.

References
1.
de Groot T, van der Hagen E, Verkaart S, te Boekhorst V, Bindels R, Hoenderop J . Role of the transient receptor potential vanilloid 5 (TRPV5) protein N terminus in channel activity, tetramerization, and trafficking. J Biol Chem. 2011; 286(37):32132-9. PMC: 3173154. DOI: 10.1074/jbc.M111.226878. View

2.
Groza T, Lopez Gomez F, Haseli Mashhadi H, Munoz-Fuentes V, Gunes O, Wilson R . The International Mouse Phenotyping Consortium: comprehensive knockout phenotyping underpinning the study of human disease. Nucleic Acids Res. 2022; 51(D1):D1038-D1045. PMC: 9825559. DOI: 10.1093/nar/gkac972. View

3.
de Groot T, Lee K, Langeslag M, Xi Q, Jalink K, Bindels R . Parathyroid hormone activates TRPV5 via PKA-dependent phosphorylation. J Am Soc Nephrol. 2009; 20(8):1693-704. PMC: 2723979. DOI: 10.1681/ASN.2008080873. View

4.
Turcu A, Clarke B . Fibrous dysplasia of bone associated with primary hyperparathyroidism. Endocr Pract. 2013; 19(2):226-30. DOI: 10.4158/EP12301.OR. View

5.
Xiong X, Chong E, Skach W . Evidence that endoplasmic reticulum (ER)-associated degradation of cystic fibrosis transmembrane conductance regulator is linked to retrograde translocation from the ER membrane. J Biol Chem. 1999; 274(5):2616-24. DOI: 10.1074/jbc.274.5.2616. View